期刊
NATURE BIOTECHNOLOGY
卷 30, 期 7, 页码 658-670出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.2287
关键词
-
资金
- Mayo Foundation
- Mayo Clinic Comprehensive Cancer Center [CA15083]
- National Cancer Institute [CA100634, CA129966, CA118488, CA129193, CA136547, CA136393]
- Richard M. Schulze Family Foundation
- Ontario Institute for Cancer Research
- Terry Fox Foundation
- Ottawa Regional Cancer Foundation
- US National Institutes of Health
- Al and Mary Agnes McQuinn and Minnesota Partnership for Biotechnology
Oncolytic virotherapy is an emerging treatment modality that uses replication-competent viruses to destroy cancers. Recent advances include preclinical proof of feasibility for a single-shot virotherapy cure, identification of drugs that accelerate intratumoral virus propagation, strategies to maximize the immunotherapeutic action of oncolytic viruses and clinical confirmation of a critical viremic threshold for vascular delivery and intratumoral virus replication. The primary clinical milestone has been completion of accrual in a phase 3 trial of intratumoral herpes simplex virus therapy using talimogene laherparepvec for metastatic melanoma. Key challenges for the field are to select 'winners' from a burgeoning number of oncolytic platforms and engineered derivatives, to transiently suppress but then unleash the power of the immune system to maximize both virus spread and anticancer immunity, to develop more meaningful preclinical virotherapy models and to manufacture viruses with orders-of-magnitude higher yields than is currently possible.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据